J&J's Cordis escapes $593M stent patent infringement loss

April 4, 2013 by Brad Perriello

A federal appeals court reverses a $593 million patent infringement loss for Johnson & Johnson's Cordis stent-making arm.

Cordis Corp.

Johnson & Johnson (NYSE:JNJ) logged a major win for its Cordis stent-making arm today when a federal appeals court overturned a lower court decision to award more than $593 million to stent pioneer Dr. Bruce Saffran for patent infringement.

Saffran alleged that Cordis violated his patent with the Cypher drug-eluting stent, leading to a jury trial that went Saffran's way.

A jury in the U.S. District Court for Eastern Texas awarded $482 million in damages to Saffran in early 2011 after finding that Cordis infringed one of his patents with its Cypher drug-eluting stent. Judge John Ward later tacked on another $111 million in pre-judgment interest, but ruled that the infringement was not willful – sparing Cordis the possibility of paying triple damages. Ward later denied a Cordis motion for a new trial.

Sign up to get our free newsletters delivered right to your inbox.

Today the U.S. Court of Appeals for the Federal Circuit overturned the infringement ruling on the grounds that the lower court's claim construction was wrong.

Comments